BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19202422)

  • 1. Rituximab for intraocular lymphoma.
    Itty S; Pulido JS
    Retina; 2009 Feb; 29(2):129-32. PubMed ID: 19202422
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical review: treatment of vitreoretinal lymphoma.
    Pe'er J; Hochberg FH; Foster CS
    Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular rituximab.
    Singh AD; Peereboom DM
    Eye (Lond); 2007 Dec; 21(12):1453-4. PubMed ID: 18159211
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy.
    Itty S; Olson JH; O'Connell DJ; Pulido JS
    Retina; 2009 Mar; 29(3):415-6. PubMed ID: 19174721
    [No Abstract]   [Full Text] [Related]  

  • 5. Intraocular use of rituximab.
    Kitzmann AS; Pulido JS; Mohney BG; Baratz KH; Grube T; Marler RJ; Donaldson MJ; O'Neill BP; Johnston PB; Johnson KM; Dixon LE; Salomao DR; Cameron JD
    Eye (Lond); 2007 Dec; 21(12):1524-7. PubMed ID: 17464308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent primary vitreoretinal and spinal cord lymphoma: a unique entity.
    Ezon IC; Barteselli G; Rosenberg J; Freeman WR
    JAMA Ophthalmol; 2014 Jul; 132(7):902-4. PubMed ID: 25010176
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing rituximab in B-cell lymphoma.
    Horning SJ
    J Clin Oncol; 2005 Feb; 23(6):1056-8. PubMed ID: 15657408
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous B-cell lymphoma treated with rituximab infusions.
    Schneider LA
    Acta Derm Venereol; 2006; 86(6):550-1. PubMed ID: 17106608
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab in diffuse large B-cell lymphoma.
    Coiffier B
    Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
    Ohguro N; Hashida N; Tano Y
    Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
    [No Abstract]   [Full Text] [Related]  

  • 11. Intraocular lymphoma.
    Goldberg S; Frenkel S; Blumenthal EZ; Solomon A; Pe'er J
    Ophthalmology; 2007 Jun; 114(6):1236-7. PubMed ID: 17544793
    [No Abstract]   [Full Text] [Related]  

  • 12. Intraocular methotrexate level after high-dose intravenous infusion.
    Henson JW; Yang J; Batchelor T
    J Clin Oncol; 1999 Apr; 17(4):1329. PubMed ID: 10561199
    [No Abstract]   [Full Text] [Related]  

  • 13. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
    Park MY; Jung HJ; Park JE; Kim YC
    Eur J Dermatol; 2010; 20(4):533-4. PubMed ID: 20542839
    [No Abstract]   [Full Text] [Related]  

  • 14. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma.
    Rey J; Wickenhauser S; Ivanov V; Coso D; Gastaut JA; Bouabdallah R
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):210. PubMed ID: 18482321
    [No Abstract]   [Full Text] [Related]  

  • 15. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C; Duval-Modeste AB; Courville P; Joly P
    Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract]   [Full Text] [Related]  

  • 16. Current status of rituximab maintenance therapy.
    Vose JM
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):968-9,1006. PubMed ID: 18277958
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Bennett M; Yegena S; Dave HP; Schechter GP
    Hematol Oncol; 2008 Jun; 26(2):114. PubMed ID: 18271062
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmacokinetics of rituximab following an intravitreal injection.
    Kim H; Csaky KG; Chan CC; Bungay PM; Lutz RJ; Dedrick RL; Yuan P; Rosenberg J; Grillo-Lopez AJ; Wilson WH; Robinson MR
    Exp Eye Res; 2006 May; 82(5):760-6. PubMed ID: 16289160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: mechanisms and applications.
    Johnson PW; Glennie MJ
    Br J Cancer; 2001 Nov; 85(11):1619-23. PubMed ID: 11742477
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of biological response modifiers to enhance the action of Rituximab.
    Taylor RP
    Leuk Res; 2005 Jun; 29(6):599-600. PubMed ID: 15863194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.